Overview

Phase 2 Fludarabine, Cytoxan and FCCAM in Untreated B-Cell Chronic Lymphocytic Leukemia

Status:
Completed

Trial end date:
2011-10-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study was to evaluate the safety and efficacy of the combination of fludarabine and cyclophosphamide in previously untreated CLL patients. Participants will receive fludarabine and cyclophosphamide on days 1, 2, and 3 of six 28-day cycles.

Phase:

Phase 2

Details

Lead Sponsor:

Steven E. Coutre

Collaborator:

Bayer

Treatments:

Alemtuzumab
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Vidarabine